192 related articles for article (PubMed ID: 34510437)
1. Sorting nexin 6 interacts with Cullin3 and regulates programmed death ligand 1 expression.
Ghosh C; Xing Y; Li S; Hoyle RG; Sun M; Li J; Sun Y
FEBS Lett; 2021 Oct; 595(20):2558-2569. PubMed ID: 34510437
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
Zhang J; Bu X; Wang H; Zhu Y; Geng Y; Nihira NT; Tan Y; Ci Y; Wu F; Dai X; Guo J; Huang YH; Fan C; Ren S; Sun Y; Freeman GJ; Sicinski P; Wei W
Nature; 2018 Jan; 553(7686):91-95. PubMed ID: 29160310
[TBL] [Abstract][Full Text] [Related]
3. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract][Full Text] [Related]
4. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
[TBL] [Abstract][Full Text] [Related]
5. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
6. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
Gao K; Shi Q; Gu Y; Yang W; He Y; Lv Z; Ding Y; Cao W; Wang C; Wan X
Cell Death Differ; 2023 Feb; 30(2):475-487. PubMed ID: 36481790
[TBL] [Abstract][Full Text] [Related]
7. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
Zhang H; Xia Y; Wang F; Luo M; Yang K; Liang S; An S; Wu S; Yang C; Chen D; Xu M; Cai M; To KKW; Fu L
Adv Sci (Weinh); 2021 May; 8(10):2003404. PubMed ID: 34026438
[TBL] [Abstract][Full Text] [Related]
8. Repression of transcriptional activity of estrogen receptor alpha by a Cullin3/SPOP ubiquitin E3 ligase complex.
Byun B; Jung Y
Mol Cells; 2008 Apr; 25(2):289-93. PubMed ID: 18414007
[TBL] [Abstract][Full Text] [Related]
9. TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
Wang L; Liu X; Han Y; Tsai HI; Dan Z; Yang P; Xu Z; Shu F; He C; Eriksson JE; Zhu H; Chen H; Cheng F
Cancer Lett; 2024 May; 590():216861. PubMed ID: 38583649
[TBL] [Abstract][Full Text] [Related]
10. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
11. Sorting nexin 6 interacts with breast cancer metastasis suppressor-1 and promotes transcriptional repression.
Rivera J; MegĂas D; Bravo J
J Cell Biochem; 2010 Dec; 111(6):1464-72. PubMed ID: 20830743
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage.
De S; Holvey-Bates EG; Mahen K; Willard B; Stark GR
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34795058
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy.
Kim SB; Hwang S; Cha JY; Lee HJ
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474186
[TBL] [Abstract][Full Text] [Related]
14. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy.
Jiang Y; Hong K; Zhao Y; Xu K
Front Immunol; 2023; 14():1228200. PubMed ID: 37415977
[TBL] [Abstract][Full Text] [Related]
16. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
[TBL] [Abstract][Full Text] [Related]
17. Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.
Yuan J; Li J; Shang M; Fu Y; Wang T
Biochem Biophys Res Commun; 2021 Jul; 561():187-194. PubMed ID: 34023785
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.
Yao H; Lan J; Li C; Shi H; Brosseau JP; Wang H; Lu H; Fang C; Zhang Y; Liang L; Zhou X; Wang C; Xue Y; Cui Y; Xu J
Nat Biomed Eng; 2019 Apr; 3(4):306-317. PubMed ID: 30952982
[TBL] [Abstract][Full Text] [Related]
19. CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein.
Dong M; Qian M; Ruan Z
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36198437
[TBL] [Abstract][Full Text] [Related]
20. Role of BCLAF-1 in PD-L1 stabilization in response to ionizing irradiation.
Ma Z; Wang H; Meng F; Han Y; Chen Y; Xiao M; Jiang H; Yu Z; Xu B
Cancer Sci; 2021 Oct; 112(10):4064-4074. PubMed ID: 34251713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]